Simon McNamara

Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma

Vânia Hungria, Paweł Robak, Marek Hus et al. · New England Journal of Medicine · 2024 · 166 citations

Medicine, Pharmacology, Pharmacotherapy +13

Quality-Adjusted Life Expectancy Norms for the English Population

Simon McNamara, P. Schneider, James Love-Koh et al. · Value in Health · 2022 · 97 citations · Full text

Social Sciences, Health Sciences, Geriatrics +10

Does the UK-public's aversion to inequalities in health differ by group-labelling and health-gain type? A choice-experiment

Simon McNamara, Aki Tsuchiya, John Holmes · Social Science & Medicine · 2020 · 26 citations

Public Health, Health Policy, Health Economics +6

Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England

Dawn Lee, A. Amadi, Javier Sabater et al. · PharmacoEconomics - Open · 2018 · 20 citations · Full text

Pharmacy, Oncology, Pharmacoeconomics +17

Decomposition of Quality-Adjusted Life Expectancy Inequalities by Mortality and Health-Related Quality of Life Dimensions

James Love-Koh, P. Schneider, Simon McNamara et al. · PharmacoEconomics · 2023 · 20 citations · Full text

Pharmacy, Pharmacoeconomics, Health Assessment +14